



Seq. Amends C/ #11  
J 3.14.03

PLEASE CHARGE ANY DEFICIENCY UP TO  
\$300.00 OR CREDIT ANY EXCESS IN THE FEES  
DUE WITH THIS DOCUMENT TO OUR  
DEPOSIT ACCOUNT NO. 19-0365

File No. IN01155 K US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Venkatraman, *et al.*

Serial No.: 09/836,636

Group Art Unit: 1653

Filed: April 17, 2001

Examiner: David Lukton

Confirmation No. 7298

For: MACROCYCLIC NS-3-SERINE PROTEASE INHIBITORS OF HEPATITIS C  
VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES

**RECEIVED**

MAR 06 2003

TECH CENTER 1600/2900

-----  
**RESPONSE TO NOTICE TO COMPLY**


Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply sent February 11, 2003 in connection with the above-referenced application. Enclosed is a paper copy of the sequence listing along with a diskette containing the sequence listing in computer readable format.

The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette, specifically the text file therein labeled "seqlist.txt", is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the text file is identical to the information originally submitted with the specification. Accordingly, no new matter has been added to the Application.

Respectfully submitted,




Feb. 27, 2003

Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

Schering-Plough Corporation  
Patent Department; K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

# COPY



Application No.: 09/836636

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:

**Applicant Must Provide:****RECEIVED**

MAR 06 2003

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

TECH CENTER 1600/2900

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
  - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
  - Email: [PATIN21HELP@uspto.gov](mailto:PATIN21HELP@uspto.gov)
  - To purchase PatentIn software: (703) 306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**